×

Dr. Satheesh CT

Dr. Satheesh CT

QualificationMBBS, MD (Paediatrics), DM (Medical Oncology), ESMO (European Society of Medical Oncology), FRCP (Edin)

Specialities Medical Oncology

Locations HCG Cancer Center - KR BLR
Book an Appointment

Introduction

Dr. Satheesh is an esteemed consultant in Medical and Haemato Oncology and the Director of Clinical Trials at the HCG Cancer Centre in Bengaluru. His expertise lies in the treatment of various solid and haematological cancers with conventional, high-dose chemotherapy, targeted chemotherapy, and immunotherapy, as well as paediatric malignancies, lymphomas, gynaecological cancers, breast and lung cancers, and cancer genomics. Dr. Satheesh has also received extensive training in the essentials of palliative care from the IAPC. With a patient-centric approach, he provides compassionate and comprehensive care to all his patients.

Area of Expertise

  • Dr. Satheesh is a consultant – medical and haemato oncology and the director of clinical trials at HCG Cancer Centre, Bengaluru.
  • Dr. Satheesh’s key areas of experience include the treatment of various solid and haematological cancers with conventional, high-dose chemotherapy, targeted chemotherapy and immunotherapy.
  • His other areas of specialisation include paediatric malignancies, lymphomas, and gynaecological cancers, along with breast and lung cancers and cancer genomics.   
  • Dr. Satheesh is well versed in delicate procedures like bone marrow aspiration and biopsy, central line insertion, lumbar puncture and autologous stem cell transplantation.
  • He also has vast experience in intraperitoneal chemotherapy, personalised medicine based on genomics and palliative care.
  • Dr. Satheesh has so far handled more than 20000 cases. 

Research & Publications

  • FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumour Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties. Canc Therapy & Oncol Int J. 2021; 19(1): 556003.
  • Landscape of clinically actionable mutations in breast cancer 'A cohort study'. Transl Oncol. 2021 Jan;14(1):100877.
  • Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies. J Cancer Res Ther. 2021 Jan-Mar;17(1):114-121.
  • The future of lung cancer therapy: Striding beyond conventional EGFR and ALK treatments. Mol Clin Oncol. 2019 Apr;10(4):469-475.
  • Intraperitoneal bevacizumab (Bev) for control of refractory malignant ascites. A single centre experience. Annals of Oncology 27 (Supplement 6): vi455–vi461, 2016.
  • Genomic Profiling in Non-Small Cell Lung Cancer: New Hope for Personalized Medicine.
  • Journal of Thoracic Oncology, Vol. 12, Issue 1, S974–S975: January 2017.
  • Indian experience of Lenvatinib in radio-iodine refractory differentiated thyroid cancer.
  • May 2018 Journal of Clinical Oncology 36(15_suppl) :e18107-e18107.
  • Landscape of clinically actionable mutations in breast cancer ‘A cohort study’. January 2021, Translational Oncology 14(1):100877.  

Medical Breakthrough

  • Dr. Satheesh is involved in various clinical trials on cancer research and has a more than 50 number of national and international publications to his credit.                               

Awards & Accolades

  • He also received extensive training in the essentials of palliative care and clinical placement in palliative care from IAPC.                             

Other Doctors